Skip to main content

Advertisement

SpringerLink
Log in

Encapsulating peritoneal sclerosis in children

  • Educational Review
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

Encapsulating peritoneal sclerosis (EPS) is a rare but extremely serious complication of peritoneal dialysis (PD). While EPS has been well recognized in adults on long-term PD, and children can spend many years on PD before a transplant becomes available, only a small number of children with EPS have been described. Two European pediatric registries have recently reported on the prevalence, potential risk factors and outcomes of EPS in children. Although the prevalence of EPS is comparable to that published in adult registries, the outcome of pediatric EPS is significantly better and carries a lower mortality. All studies have shown a greater risk of EPS with a longer dialysis vintage, but it is not known why some individuals are susceptible to EPS development. In this review we discuss current views on the epidemiology, pathogenesis and management strategies for EPS. The hope of the authors is that this review will alert pediatric nephrologists to this rare but extremely serious complication of chronic PD. In the future, collaborative research and the establishment of a pediatric EPS registry may be of importance in helping pediatric nephrologists to recognize the early warning signs of EPS development and thereby to develop strategies for its prevention and optimal management.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

References

  1. Hoshii S, Honda M, Itami N, Oh S, Matsumura C, Moriya S, Mori M, Hatae K, Ito Y, Karashima S (2000) Sclerosing encapsulating peritonitis in pediatric peritoneal dialysis patients. Pediatr Nephrol 14:275–279

    Article  PubMed  CAS  Google Scholar 

  2. Shroff R, Stefanidis CJ, Askiti V, Edefonti A, Testa S, Ekim M, Kavaz A, Ariceta G, Bakkaloglu S, Fischbach M, Klaus G, Zurowska A, Holtta T, Jankauskiene A, Vondrak K, Walle JV, Schmitt CP, Watson AR (2013) Encapsulating peritoneal sclerosis in children on chronic PD: a survey from the European Paediatric Dialysis Working Group. Nephrol Dial Transplant 28:1908–1914

    Article  PubMed  CAS  Google Scholar 

  3. Vidal E, Edefonti A, Puteo F, Chimenz R, Gianoglio B, Lavoratti G, Leozappa G, Maringhini S, Mencarelli F, Pecoraro C, Ratsch IM, Cannavo R, De PT, Testa S, Murer L, Verrina E (2013) Encapsulating peritoneal sclerosis in paediatric peritoneal dialysis patients: the experience of the Italian Registry of Pediatric Chronic Dialysis. Nephrol Dial Transplant 28:1603–1609

    Article  PubMed  CAS  Google Scholar 

  4. Foo KT, Ng KC, Rauff A, Foong WC, Sinniah R (1978) Unusual small intestinal obstruction in adolescent girls: the abdominal cocoon. Br J Surg 65:427–430

    Article  PubMed  CAS  Google Scholar 

  5. Brown P, Baddeley H, Read AE, Davies JD, McGarry J (1974) Sclerosing peritonitis, an unusual reaction to a beta-adrenergic-blocking drug (practolol). Lancet 2:1477–1481

    Article  PubMed  CAS  Google Scholar 

  6. Gandhi VC, Humayun HM, Ing TS, Daugirdas JT, Jablokow VR, Iwatsuki S, Geis WP, Hano JE (1980) Sclerotic thickening of the peritoneal membrane in maintenance peritoneal dialysis patients. Arch Intern Med 140:1201–1203

    Article  PubMed  CAS  Google Scholar 

  7. Niaudet P, Berard E, Revillon Y, Lothon M, Broyer M (1987) Sclerosing encapsulating peritonitis in children. Contrib Nephrol 57:230–238

    PubMed  CAS  Google Scholar 

  8. Hoshii S, Honda M (2002) High incidence of encapsulating peritoneal sclerosis in pediatric patients on peritoneal dialysis longer than 10 years. Perit Dial Int 22:730–731

    PubMed  CAS  Google Scholar 

  9. Araki Y, Hataya H, Tanaka Y, Fukuzawa R, Ikeda M, Kawamura K, Honda M (2000) Long-term peritoneal dialysis is a risk factor of sclerosing encapsulating peritonitis for children. Perit Dial Int 20:445–451

    PubMed  CAS  Google Scholar 

  10. Ekim M, Fitoz S, Yagmurlu A, Ensari A, Yuksel S, Acar B, Ozcakar ZB, Kendirli T, Bingoler B, Yalcinkaya F (2005) Encapsulating peritoneal sclerosis in paediatric peritoneal dialysis patients. Nephrology (Carlton) 10:341–343

    Article  Google Scholar 

  11. von Schnakenburg C, Pohl M, Häffner K, Zimmerhackl LB, Brandis M (2005) Sclerosing peritonitis without reduced ultrafiltration as complication of peritoneal dialysis. Klin Padiatr 217(1):41–44

    Article  Google Scholar 

  12. Tan FL, Loh D, Prabhakaran K (2005) Sclerosing encapsulating peritonitis in a child secondary to peritoneal dialysis. J Pediatr Surg 40(5):e21–e23

    Article  PubMed  Google Scholar 

  13. Garces–Inigo EF, Lee EY (2008) Sclerosing encapsulating peritonitis. Pediatr Radiol 38(2):245

    Article  PubMed  Google Scholar 

  14. Marsenic O, Kaplan B, Meyers KE (2009) Chronic abdominal pain in a patient on chronic peritoneal dialysis: question. Pediatr Nephrol 24(1):49

    Article  PubMed  Google Scholar 

  15. Tan R, Betjes M, Cransberg K (2011) Post–transplantation encapsulating peritoneal sclerosis in a young child. Nephrol Dial Transplant 26:3822–3824

    Article  PubMed  Google Scholar 

  16. da Silva N, Rocha S, Rocha L, Faria S, Costa T, Mota C (2012) Post-transplantation encapsulating peritoneal sclerosis in a pediatric patient. Pediatr Nephrol 27:1583–1588

    Google Scholar 

  17. Kawaguchi Y, Saito A, Kawanishi H, Nakayama M, Miyazaki M, Nakamoto H, Tranaeus A (2005) Recommendations on the management of encapsulating peritoneal sclerosis in Japan, 2005: diagnosis, predictive markers, treatment, and preventive measures. Perit Dial Int 25[Suppl 4]:S83–S95

    PubMed  Google Scholar 

  18. Tarzi RM, Lim A, Moser S, Ahmad S, George A, Balasubramaniam G, Clutterbuck EJ, Gedroyc W, Brown EA (2008) Assessing the validity of an abdominal CT scoring system in the diagnosis of encapsulating peritoneal sclerosis. Clin J Am Soc Nephrol 3:1702–1710

    Article  PubMed  PubMed Central  Google Scholar 

  19. Augustine T, Brown PW, Davies SD, Summers AM, Wilkie ME (2009) Encapsulating peritoneal sclerosis: clinical significance and implications. Nephron Clin Pract 111:c149–c154

    Article  PubMed  CAS  Google Scholar 

  20. Nakamoto H (2005) Encapsulating peritoneal sclerosis–a clinician’s approach to diagnosis and medical treatment. Perit Dial Int 25[Suppl 4]:S30–S38

    PubMed  Google Scholar 

  21. Coester AKR, Boeschoten E (2008) Nephrologists’ Perception of PD in the Netherlands. Perit Dial Int 28[Suppl 4]:S88

    Google Scholar 

  22. Brown MC, Simpson K, Kerssens JJ, Mactier RA (2009) Encapsulating peritoneal sclerosis in the new millennium: a national cohort study. Clin J Am Soc Nephrol 4:1222–1229

    Article  PubMed  PubMed Central  Google Scholar 

  23. Korte MR, Boeschoten EW, Betjes MG (2009) The Dutch EPS Registry: increasing the knowledge of encapsulating peritoneal sclerosis. Neth J Med 67:359–362

    PubMed  CAS  Google Scholar 

  24. Nomoto Y, Kawaguchi Y, Kubo H, Hirano H, Sakai S, Kurokawa K (1996) Sclerosing encapsulating peritonitis in patients undergoing continuous ambulatory peritoneal dialysis: a report of the Japanese Sclerosing Encapsulating Peritonitis Study Group. Am J Kidney Dis 28:420–427

    Article  PubMed  CAS  Google Scholar 

  25. Marinangeli G, Cabiddu G, Neri L, Viglino G, Russo R, Teatini U (2012) Old and new perspectives on peritoneal dialysis in Italy emerging from the Peritoneal Dialysis Study Group Census. Perit Dial Int 32:558–565

    Article  PubMed  PubMed Central  Google Scholar 

  26. Williams JD, Craig KJ, von RC, Topley N, Williams GT (2003) The natural course of peritoneal membrane biology during peritoneal dialysis. Kidney Int Suppl 2003:S43-S49

  27. Garosi G (2009) Different aspects of peritoneal damage: fibrosis and sclerosis. Contrib Nephrol 163:45–53

    Article  PubMed  Google Scholar 

  28. Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE (2000) Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 12:1232–1235

    Article  PubMed  CAS  Google Scholar 

  29. Honda K, Oda H (2005) Pathology of encapsulating peritoneal sclerosis. Perit Dial Int 25[Suppl 4]:S19–S29

    PubMed  Google Scholar 

  30. Wang J, Jiang ZP, Su N, Fan JJ, Ruan YP, Peng WX, Li YF, Yu XQ (2013) The role of peritoneal alternatively activated macrophages in the process of peritoneal fibrosis related to peritoneal dialysis. Int J Mol Sci 14:10369–10382

    Article  PubMed  PubMed Central  Google Scholar 

  31. Stoenoiu MS, De Vriese AS, Brouet A, Moulin P, Feron O, Lameire N, Devuyst O (2002) Experimental diabetes induces functional and structural changes in the peritoneum. Kidney Int 62:668–678

    Article  PubMed  Google Scholar 

  32. Park SH, Kim YL, Lindholm B (2008) Experimental encapsulating peritoneal sclerosis models: pathogenesis and treatment. Perit Dial Int 28[Suppl 5]:S21–S28

    PubMed  CAS  Google Scholar 

  33. Schwenger V, Morath C, Salava A, Amann K, Seregin Y, Deppisch R, Ritz E, Bierhaus A, Nawroth PP, Zeier M (2006) Damage to the peritoneal membrane by glucose degradation products is mediated by the receptor for advanced glycation end-products. J Am Soc Nephrol 17:199–207

    Article  PubMed  CAS  Google Scholar 

  34. Park MS, Lee HA, Chu WS, Yang DH, Hwang SD (2000) Peritoneal accumulation of AGE and peritoneal membrane permeability. Perit Dial Int 20:452–460

    PubMed  CAS  Google Scholar 

  35. Io H, Hamada C, Ro Y, Ito Y, Hirahara I, Tomino Y (2004) Morphologic changes of peritoneum and expression of VEGF in encapsulated peritoneal sclerosis rat models. Kidney Int 65:1927–1936

    Article  PubMed  CAS  Google Scholar 

  36. Schilte MN, Celie JW, Wee PM, Beelen RH, van den Born J (2009) Factors contributing to peritoneal tissue remodeling in peritoneal dialysis. Perit Dial Int 29:605–617

    PubMed  CAS  Google Scholar 

  37. Aguilera A, Yanez-Mo M, Selgas R, Sanchez-Madrid F, Lopez-Cabrera M (2005) Epithelial to mesenchymal transition as a triggering factor of peritoneal membrane fibrosis and angiogenesis in peritoneal dialysis patients. Curr Opin Investig Drugs 6:262–268

    PubMed  CAS  Google Scholar 

  38. Aroeira LS, Aguilera A, Selgas R, Ramírez-Huesca M, Pérez-Lozano ML, Cirugeda A, Bajo MA, del Peso G, Sanchez-Tomero JA, Jiménez-Heffernan JA, López-Cabrera M (2005) Mesenchymal conversion of mesothelial cells as a mechanism responsible for high solute transport rate in peritoneal dialysis: role of vascular endothelial growth factor. Am J Kidney Dis 46:938–948

    Article  PubMed  CAS  Google Scholar 

  39. Sitter T, Spannagl M, Schiffl H, Held E, van Hinsbergh V, Kooistra T (1995) Imbalance between intraperitoneal coagulation and fibrinolysis during peritonitis of CAPD patients: the role of mesothelial cells. Nephrol Dial Transplant 10:677–683

    PubMed  CAS  Google Scholar 

  40. Holmdahl L, Kotseos K, Bergstrom M, Falk P, Ivarsson ML, Chegini N (2001) Overproduction of transforming growth factor-beta1 (TGF-beta1) is associated with adhesion formation and peritoneal fibrinolytic impairment. Surgery 129:626–632

    Article  PubMed  CAS  Google Scholar 

  41. Rottembourg J, Brouard R, Issad B, Allouache M, Ghali B, Boudjemaa A (1987) Role of acetate in loss of ultrafiltration during CAPD. Contrib Nephrol 57:197–206

    PubMed  CAS  Google Scholar 

  42. Korte MR, Sampimon DE, Lingsma HF, Fieren MW, Looman CW, Zietse R, Weimar W, Betjes MG (2011) Risk factors associated with encapsulating peritoneal sclerosis in Dutch EPS study. Perit Dial Int 31:269–278

    Article  PubMed  Google Scholar 

  43. Moriishi M, Kawanishi H, Kawai T, Takahashi S, Hirai T, Shishida M, Watanabe H, Takahashi N (2002) Preservation of peritoneal catheter for prevention of encapsulating peritoneal sclerosis. Adv Perit Dial 18:149–153

    PubMed  Google Scholar 

  44. Wolfson M, Piraino B, Hamburger RJ, Morton AR (2002) A randomized controlled trial to evaluate the efficacy and safety of icodextrin in peritoneal dialysis. Am J Kidney Dis 40:1055–1065

    Article  PubMed  CAS  Google Scholar 

  45. Davies SJ, Brown EA, Frandsen NE, Rodrigues AS, Rodriguez-Carmona A, Vychytil A, Macnamara E, Ekstrand A, Tranaeus A, Filho JC (2005) Longitudinal membrane function in functionally anuric patients treated with APD: data from EAPOS on the effects of glucose and icodextrin prescription. Kidney Int 67:1609–1615

    Article  PubMed  CAS  Google Scholar 

  46. Guo A, Wolfson M, Holt R (2002) Early quality of life benefits of icodextrin in peritoneal dialysis. Kidney Int Suppl (81):S72–S79

  47. Habib AM, Preston E, Davenport A (2010) Risk factors for developing encapsulating peritoneal sclerosis in the icodextrin era of peritoneal dialysis prescription. Nephrol Dial Transplant 25:1633–1638

    Article  PubMed  CAS  Google Scholar 

  48. Parikova A, Zweers MM, Struijk DG, Krediet RT (2003) Peritoneal effluent markers of inflammation in patients treated with icodextrin-based and glucose-based dialysis solutions. Adv Perit Dial 19:186–190

    PubMed  Google Scholar 

  49. Parikova A, Struijk DG, Zweers MM, Langedijk M, Schouten N, van den Berg N, Duis S, Krediet RT (2007) Does the biocompatibility of the peritoneal dialysis solution matter in assessment of peritoneal function? Perit Dial Int 27:691–696

    PubMed  CAS  Google Scholar 

  50. Krediet RT (2010) Effects of icodextrin on the peritoneal membrane. Nephrol Dial Transplant 25:1373–1375

    Article  PubMed  CAS  Google Scholar 

  51. van Westrhenen R, Aten J, Hajji N, de Boer OJ, Kunne C, de Waart DR, Krediet RT (2007) Cyclosporin A induces peritoneal fibrosis and angiogenesis during chronic peritoneal exposure to a glucose-based, lactate-buffered dialysis solution in the rat. Blood Purif 25:466–472

    Article  PubMed  Google Scholar 

  52. Maluccio M, Sharma V, Lagman M, Vyas S, Yang H, Li B, Suthanthiran M (2003) Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression. Transplantation 76:597–602

    Article  PubMed  CAS  Google Scholar 

  53. Korte MR, Habib SM, Lingsma H, Weimar W, Betjes MG (2011) Posttransplantation encapsulating peritoneal sclerosis contributes significantly to mortality after kidney transplantation. Am J Transplant 11:599–605

    Article  PubMed  CAS  Google Scholar 

  54. Oules R, Challah S, Brunner FP (1988) Case-control study to determine the cause of sclerosing peritoneal disease. Nephrol Dial Transplant 3:66–69

    PubMed  CAS  Google Scholar 

  55. Sampimon DE, Vlijm A, Phoa SS, Krediet RT, Struijk DG (2010) Encapsulating peritoneal sclerosis in a peritoneal dialysis patient using biocompatible fluids only: is Alport syndrome a risk factor? Perit Dial Int 30:240–242

    Article  PubMed  Google Scholar 

  56. Sampimon DE, Coester AM, Struijk DG, Krediet RT (2007) Time course of peritoneal transport parameters in peritoneal dialysis patients who develop peritoneal sclerosis. Adv Perit Dial 23:107–111

    PubMed  Google Scholar 

  57. Sampimon DE, Korte MR, Barreto DL, Vlijm A, de Waart R, Struijk DG, Krediet RT (2010) Early diagnostic markers for encapsulating peritoneal sclerosis: a case-control study. Perit Dial Int 30:163–169

    Article  PubMed  CAS  Google Scholar 

  58. Goodlad C, Tarzi R, Gedroyc W, Lim A, Moser S, Brown EA (2011) Screening for encapsulating peritoneal sclerosis in patients on peritoneal dialysis: role of CT scanning. Nephrol Dial Transplant 26:1374–1379

    Article  PubMed  Google Scholar 

  59. Garosi G, Oreopoulos DG (2009) No need for an “expiry date” in chronic peritoneal dialysis to prevent encapsulating peritoneal sclerosis. Int Urol Nephrol 41:903–907

    Article  PubMed  Google Scholar 

  60. Afthentopoulos IE, Passadakis P, Oreopoulos DG, Bargman J (1998) Sclerosing peritonitis in continuous ambulatory peritoneal dialysis patients: one center’s experience and review of the literature. Adv Ren Replace Ther 5:157–167

    PubMed  CAS  Google Scholar 

  61. Kuriyama S, Tomonari H (2001) Corticosteroid therapy in encapsulating peritoneal sclerosis. Nephrol Dial Transplant 16:1304–1305

    Article  PubMed  CAS  Google Scholar 

  62. Mori Y, Matsuo S, Sutoh H, Toriyama T, Kawahara H, Hotta N (1997) A case of a dialysis patient with sclerosing peritonitis successfully treated with corticosteroid therapy alone. Am J Kidney Dis 30:275–278

    Article  PubMed  CAS  Google Scholar 

  63. Habib SM, Betjes MG, Fieren MW, Boeschoten EW, Abrahams AC, Boer WH, Struijk DG, Ruger W, Krikke C, Westerhuis R, de Sevaux RG, van der Sande FM, Gaasbeek A, Korte MR (2011) Management of encapsulating peritoneal sclerosis: a guideline on optimal and uniform treatment. Neth J Med 69:500–507

    PubMed  CAS  Google Scholar 

  64. Wong CF, Beshir S, Khalil A, Pai P, Ahmad R (2005) Successful treatment of encapsulating peritoneal sclerosis with azathioprine and prednisolone. Perit Dial Int 25:285–287

    PubMed  Google Scholar 

  65. Lafrance JP, Letourneau I, Ouimet D, Bonnardeaux A, Leblanc M, Mathieu N, Pichette V (2008) Successful treatment of encapsulating peritoneal sclerosis with immunosuppressive therapy. Am J Kidney Dis 51:e7–e10

    Article  PubMed  Google Scholar 

  66. Ceri M, Unverdi S, Dogan M, Unverdi H, Karaca G, Kocak G, Kurultak I, Akbal E, Can M, Duranay M (2012) Effect of sirolimus on the regression of peritoneal sclerosis in an experimental rat model. Int Urol Nephrol 44:977–982

    Article  PubMed  CAS  Google Scholar 

  67. Rajani R, Smyth J, Koffman CG, Abbs I, Goldsmith DJ (2002) Differential Effect of sirolimus vs prednisolone in the treatment of sclerosing encapsulating peritonitis. Nephrol Dial Transplant 17:2278–2280

    Article  PubMed  CAS  Google Scholar 

  68. van Bommel EF, Hendriksz TR, Huiskes AW, Zeegers AG (2006) Brief communication: tamoxifen therapy for nonmalignant retroperitoneal fibrosis. Ann Intern Med 144:101–106

    Article  PubMed  Google Scholar 

  69. Guest S (2009) Tamoxifen therapy for encapsulating peritoneal sclerosis: mechanism of action and update on clinical experiences. Perit Dial Int 29:252–255

    PubMed  CAS  Google Scholar 

  70. Korte MR, Fieren MW, Sampimon DE, Lingsma HF, Weimar W, Betjes MG (2011) Tamoxifen is associated with lower mortality of encapsulating peritoneal sclerosis: results of the Dutch Multicentre EPS Study. Nephrol Dial Transplant 26:691–697

    Article  PubMed  CAS  Google Scholar 

  71. Balasubramaniam G, Brown EA, Davenport A, Cairns H, Cooper B, Fan SL, Farrington K, Gallagher H, Harnett P, Krausze S, Steddon S (2009) The Pan-Thames EPS study: treatment and outcomes of encapsulating peritoneal sclerosis. Nephrol Dial Transplant 24:3209–3215

    Article  PubMed  Google Scholar 

  72. Kyuden Y, Ito T, Masaki T, Yorioka N, Kohno N (2005) Tgf-beta1 induced by high glucose is controlled by angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker on cultured human peritoneal mesothelial cells. Perit Dial Int 25:483–491

    PubMed  CAS  Google Scholar 

  73. Bozkurt D, Cetin P, Sipahi S, Hur E, Nar H, Ertilav M, Sezak M, Duman S (2008) The effects of renin–angiotensin system inhibition on regression of encapsulating peritoneal sclerosis. Perit Dial Int 28[Suppl 5]:S38–S42

    PubMed  CAS  Google Scholar 

  74. Kolesnyk I, Dekker FW, Noordzij M, le Cessie S, Struijk DG, Krediet RT (2007) Impact of ACE inhibitors and AII receptor blockers on peritoneal membrane transport characteristics in long-term peritoneal dialysis patients. Perit Dial Int 27:446–453

    PubMed  CAS  Google Scholar 

  75. Kolesnyk I, Noordzij M, Dekker FW, Boeschoten EW, Krediet RT (2009) A positive effect of AII inhibitors on peritoneal membrane function in long-term PD patients. Nephrol Dial Transplant 24:272–277

    Article  PubMed  CAS  Google Scholar 

  76. Sampimon DE, Kolesnyk I, Korte MR, Fieren MW, Struijk DG, Krediet RT (2010) Use of angiotensin II inhibitors in patients that develop encapsulating peritoneal sclerosis. Perit Dial Int 30:656–659

    Article  PubMed  Google Scholar 

  77. Kim CS, Joo SY, Lee KE, Choi JS, Bae EH, Ma SK, Kim SH, Lee J, Kim SW (2013) Paricalcitol attenuates 4-hydroxy-2-hexenal-induced inflammation and epithelial–mesenchymal transition in human renal proximal tubular epithelial cells. PLoS One 8:e63186

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  78. Kawanishi H, Shintaku S, Moriishi M, Dohi K, Tsuchiya S (2011) Seventeen years’ experience of surgical options for encapsulating peritoneal sclerosis. Adv Perit Dial 27:53–58

    PubMed  Google Scholar 

  79. de Freitas D, Jordaan A, Williams R, Alderdice J, Curwell J, Hurst H, Hutchison A, Brenchley PE, Augustine T, Summers AM (2008) Nutritional management of patients undergoing surgery following diagnosis with encapsulating peritoneal sclerosis. Perit Dial Int 28:271–276

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nephrology, “P. & A. Kyriakou” Children’s Hospital of Athens, Thivon and Levadias Str, Goudi, 14562, Athens, Greece

    Constantinos J. Stefanidis

  2. Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK

    Rukshana Shroff

Authors
  1. Constantinos J. Stefanidis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rukshana Shroff
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Constantinos J. Stefanidis.

Additional information

Answers:

1. C

2. C

3. A

4. D

5. B

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stefanidis, C.J., Shroff, R. Encapsulating peritoneal sclerosis in children. Pediatr Nephrol 29, 2093–2103 (2014). https://doi.org/10.1007/s00467-013-2672-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-013-2672-8

Keywords

Search

Navigation